373 related articles for article (PubMed ID: 8542950)
21. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
Cortelazzo S; Viero P; Bellavita P; Rossi A; Buelli M; Borleri GM; Marziali S; Bassan R; Comotti B; Rambaldi A
J Clin Oncol; 1995 Apr; 13(4):935-41. PubMed ID: 7535843
[TBL] [Abstract][Full Text] [Related]
22. Autologous bone marrow transplantation in non-Hodgkin's lymphoma patients: effect of a brief course of G-CSF on harvest and recovery.
Damiani D; Grimaz S; Infanti L; Sperotto A; Silvestri F; Geromin A; Cerno M; Savignano C; Michieli M; Skert C; Fanin R; Baccarani M
Bone Marrow Transplant; 1999 Oct; 24(7):757-61. PubMed ID: 10516679
[TBL] [Abstract][Full Text] [Related]
23. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
[TBL] [Abstract][Full Text] [Related]
24. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas.
Brice P; Divine M; Marolleau JP; Haioun C; Dalcortivo L; Sitthy X; Beaujean F; Norol F; Benbunan M; Reyes F
Bone Marrow Transplant; 1994 Jul; 14(1):51-5. PubMed ID: 7524907
[TBL] [Abstract][Full Text] [Related]
25. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
Martínez C; Sureda A; Martino R; Cancelas JA; Madoz P; García J; Brunet S
Bone Marrow Transplant; 1997 Nov; 20(10):855-8. PubMed ID: 9404926
[TBL] [Abstract][Full Text] [Related]
26. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
29. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment.
Koç ON; Gerson SL; Phillips GL; Cooper BW; Kutteh L; Van Zant G; Reece DE; Fox RM; Schupp JE; Tainer N; Lazarus HM
Bone Marrow Transplant; 1998 Feb; 21(4):337-43. PubMed ID: 9509966
[TBL] [Abstract][Full Text] [Related]
30. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
[TBL] [Abstract][Full Text] [Related]
31. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
32. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
[TBL] [Abstract][Full Text] [Related]
33. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
34. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[TBL] [Abstract][Full Text] [Related]
36. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.
Kiss JE; Rybka WB; Winkelstein A; deMagalhaes-Silverman M; Lister J; D'Andrea P; Ball ED
Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238
[TBL] [Abstract][Full Text] [Related]
37. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
Altés A; López R; Martino R; Martinez C; Cabezudo E; Muñoz L; Santamaría A; Perea G; Briones J; Salar A; Sureda A; Brunet S; Madoz P; Sierra J
Bone Marrow Transplant; 2000 Jul; 26(2):127-32. PubMed ID: 10918421
[TBL] [Abstract][Full Text] [Related]
38. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
39. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
40. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
